

Benchmark Rates Liquidity Monitor

April 2021 | Issue 4

ESTR volumes are up significantly in April, while EURIBOR swaps trading is more muted. SONIA volumes are now well above GBP LIBOR swaps trading across nearly all tenors. While USD LIBOR volumes are down, SOFR volumes are relatively flat in April.

EUR

ESTR monthly trading volume in April reached 45bln according to the Swapsinfo data. That is compared to 10-20bln. EUR range observed since H2 2020.

In April trading volumes in 30Y tenor in ESTR swaps overtook EONIA volumes at 2.25bln. vs 1.25bln. EUR respectively. 20Y point in ESTR volume was also higher than in EONIA. In both cases it was the first time ESTR volumes were higher than EONIA.

GBP

The ratio of SONIA to GBP LIBOR trade count has increased significantly: SONIA swaps across all tenors account now at least for 100% of GBP LIBOR swaps. Trade count and volume figures in 5Y and 10Y points in SONIA are at 2x - 3x multiples of GBP LIBOR trading. This is reflective of the Bank of England working group's recommendations to shift most linear swap liquidity to SONIA from end Q1 onwards (link).

USD


In April, USD LIBOR monthly trade volume declined 33% month-on-month to 177.2bln, according to Swapsinfo data.

Overall trade volumes remain concentrated at the short end of the curve. However, trading volumes in 30Y tenor SOFR slightly surpassed Fed Funds OIS volumes.


The ratio of OIS to USD LIBOR trade count remained relatively stable with OIS swaps across 5Y to 30Y tenors accounting for less than 10% of USD LIBOR swaps. 2Y OIS swaps trade count is at 20% of USD LIBOR.

IRS AND OIS TOTAL LIQUIDITY


1: EURIBOR AND ESTR MONTHLY TRADING VOLUME (USD BLN)




2: EURIBOR AND ESTR MONTHLY TRADE COUNT




3: GBP LIBOR AND SONIA MONTHLY TRADING VOLUME (USD BLN)




4: GBP LIBOR AND SONIA MONTHLY TRADE COUNT




5: USD LIBOR AND SOFR MONTHLY TRADING VOLUME (USD BLN)




6: USD LIBOR AND SOFR MONTHLY TRADE COUNT



7: JPY LIBOR AND TONA MONTHLY TRADING VOLUME (USD BLN)




8: JPY LIBOR AND TONA MONTHLY TRADE COUNT




IRS AND OIS LIQUIDITY PER TENOR


9: ESTR AND EONIA OIS TO EURIBOR IRS MONTHLY VOLUME RATIO




10: ESTR AND EONIA OIS TO EURIBOR IRS MONTHLY TRADE COUNT RATIO




11: SONIA OIS TO GBP LIBOR IRS MONTHLY VOLUME RATIO




12: SONIA OIS TO GBP LIBOR IRS MONTHLY TRADE COUNT RATIO




13: OIS TO USD LIBOR IRS MONTHLY VOLUME RATIO




14: OIS TO USD LIBOR IRS MONTHLY TRADE COUNT RATIO



15: OIS TO JPY LIBOR IRS MONTHLY VOLUME RATIO




16: OIS TO JPY LIBOR IRS MONTHLY TRADE COUNT RATIO




EUR OIS LIQUIDITY - APRIL 2021


17: ESTR VS EONIA TRADE VOLUME PER TENOR (EUR BLN)




19: FED FUNDS VS SOFR TRADE VOLUME PER TENOR (EUR BLN)



18: ESTR VS EONIA TRADE COUNT PER TENOR



20: FED FUNDS VS SOFR TRADE COUNT PER TENOR



MILLIMAN BENCHMARK RATES LIQUIDITY MONITOR

Disclaimers

The information, products, or services described or referenced herein are intended to be for informational purposes only. This material is not intended to be a recommendation, offer, solicitation or advertisement to buy or sell any securities, securities related product or service, or investment strategy, nor is it intended to be to be relied upon as a forecast, research or investment advice.

The products or services described or referenced herein may not be suitable or appropriate for the recipient. Many of the products and services described or referenced herein involve significant risks, and the recipient should not make any decision or enter into any transaction unless the recipient has fully understood all such risks and has independently determined that such decisions or transactions are appropriate for the recipient. Investment involves risks. Any discussion of risks contained herein with respect to any product or service should not be considered to be a disclosure of all risks or a complete discussion of the risks involved. Investing in foreign securities is subject to greater risks including: currency fluctuation, economic conditions, and different governmental and accounting standards.

The recipient should not construe any of the material contained herein as investment, hedging, trading, legal, regulatory, tax, accounting or other advice. The recipient should not act on any information in this document without consulting its investment, hedging, trading, legal, regulatory, tax, accounting and other advisors. Information herein has been obtained from sources we believe to be reliable but neither Milliman Financial Strategies B.V. ("MFS B.V.") nor its parents, subsidiaries or affiliates warrant its completeness or accuracy. No responsibility can be accepted for errors of facts obtained from third parties.

The materials in this document represent the opinion of the authors at the time of authorship; they may change, and are not representative of the views of MFS B.V. or its parents, subsidiaries, or affiliates. MFS B.V. does not certify the information, nor does it guarantee the accuracy and completeness of such information. Use of such information is voluntary and should not be relied upon unless an independent review of its accuracy and completeness has been performed. Materials may not be reproduced without the express consent of MFS B.V.

For financial professional use only. Not intended for public distribution.

Milliman

Milliman is among the world's largest providers of actuarial and related products and services. The firm has consulting practices in life insurance and financial services, property & casualty insurance, healthcare, and employee benefits. Founded in 1947, Milliman is an independent firm with offices in major cities around the globe.

milliman.com

For more information, please contact your Milliman consultant.

© 2021 Milliman, Inc. All Rights Reserved. The materials in this document represent the opinion of the authors and are not representative of the views of Milliman, Inc. Milliman does not certify the information, nor does it guarantee the accuracy and completeness of such information. Use of such information is voluntary and should not be relied upon unless an independent review of its accuracy and completeness has been performed. Materials may not be reproduced without the express consent of Milliman.